ABBV-400(Telisotuzumab Adizutecan)是艾伯维筛选了超过400种连接子-载荷后得到cMET靶向ADC,,也是艾伯维开发的第二款cMET靶向ADC,抗体部分仍然为telisotuzumab与Teliso-V保持一致,载荷为TOPO1i。 ABBV-400推测结构 刚刚结束的2024年ESMO会议上,艾伯维公布了NCT...
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress February 8th 2025 The OncFive: Top Oncology Articles for the Week of 2/2 February 8th 2025 Cabozantinib Plus Nivolumab Demonstrates Disease Control in Refractory MSS mCRCLatest...